A Phase 1 Study of MLN9708 in Adult Patients With Advanced Nonhematologic Malignancies



Status:Archived
Conditions:Cancer, Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:March 2009
End Date:June 2012

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies


This is an open-label, multicenter, phase 1, dose escalation study of MLN9708. The primary
purpose of this study is to determine the safety profile, establish the maximum tolerated
dose, and inform the phase 2 dose of MLN9708 administered intravenously in patients with
nonhematologic malignancies.



We found this trial at
2
sites
H. Lee Moffitt Cancer Center & Research Institute
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Sarah Cannon Cancer Center
230 25th Ave N
Nashville, Tennessee 37203
(615) 329-7274
Sarah Cannon Cancer Center People who live with cancer
?
mi
from
Nashville, TN
Click here to add this to my saved trials